Investors
Phase II company positioned for growth
Cereno Scientific is well-positioned for strong growth in an attractive cardiovascular and rare diseases market with a diversified portfolio of clinical and preclinical candidates.
Pipeline
Therapeutics for patients with high unmet medical needs
Cereno has a project portfolio targeting diseases with high unmet medical needs. The aim is to develop treatments that can enhance and extend the lives of affected patients. The portfolio comprises a Phase II program, one Phase I program and one preclinical program.
Therapeutic focus
Better efficacy and fewer side effects in focus
Cardiovascular disease is the number 1 cause of death globally, killing nearly twice as many people as cancer. Cereno has an extensive experience in cardiovascular diseases and works toward the aim of developing innovative, effective and safe treatments for patients affected by diseases where great unmet needs persist.